Systematic review and meta-analysis:pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis by Bek, S et al.
Syddansk Universitet
Systematic review and meta-analysis
pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis
Sørensen, Signe Bek; Bojesen, Anders; Nielsen, Jakob V.; Sode, Jacob; Bank, Steffen;
Vogel, U; Andersen, Vibeke
Published in:
Pharmacogenomics Journal
DOI:
10.1038/tpj.2017.26
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-SA
Citation for pulished version (APA):
Bek, S., Bojesen, A. B., Nielsen, J. V., Sode, J., Bank, S., Vogel, U., & Andersen, V. (2017). Systematic review
and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.
Pharmacogenomics Journal, 17, 403–411. DOI: 10.1038/tpj.2017.26
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
OPEN
REVIEW
Systematic review and meta-analysis: pharmacogenetics of
anti-TNF treatment response in rheumatoid arthritis
S Bek1, AB Bojesen1,2, JV Nielsen1, J Sode1, S Bank1, U Vogel2,3 and V Andersen1,4,5,6
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease that affects ~ 1% of the Caucasian population. Over the last decades, the
availability of biological drugs targeting the proinﬂammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the
treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the
status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original
data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated
by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA
(19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB
and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found
that biomarkers for clinical treatment selection are not yet available.
The Pharmacogenomics Journal (2017) 17, 403–411; doi:10.1038/tpj.2017.26; published online 13 June 2017
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease that
affects ~ 1% of the Caucasian population.1 Disease onset typically
manifests at age of 35–50 years, and females are affected 2.5 times
more frequently than males. RA is characterised by synovial
inﬂammation of joints most often affecting the joints of hands,
wrist and feet, potentially leading to joint destruction, and
functional disability. Furthermore, extra-articular manifestations
may occur, for example, osteoporosis, vasculitis or interstitial lung
disease. The manifestations are consequences of a chronically
activated immune system. Both proinﬂammatory cytokines as
tumour necrosis factor (TNF), interleukin (IL)-6, IL-8, GM-CSF, IL-1
and anti-inﬂammatory cytokines as IL-10 are involved. TNFα is a
member of the TNF family of regulators of immune and
inﬂammatory responses, which may also mediate cell death.2
In the 1980s, it was shown that TNFα has a prominent role in
RA,3–5 and over the past decades, the availability of drugs
targeting tumour necrosis factor α (anti-TNF) has improved the
treatment of RA patients. Nevertheless, only 60–70% of patients
have a good to moderate response to the anti-TNF treatment,
whereas 30–40% have no or insufﬁcient response.2,6 Apart from
anti-TNF drugs, biological compounds targeting CD20, T-lympho-
cyte antigen 4 immunoglobulin, interleukin 6 receptor and B-cells
have been developed.7,8 Until now, the treatment paradigm has
been ‘one drug suits all’. Thereby, patients may remain in high
disease activity, with irreversible joint damage as a possible
consequence. Pharmacogenetics may identify the individual
patient’s signature that may help guide the treatment selection
(reviewed in refs 9,10). Genetic variants may impact anti-TNF drug
response.9–16 They may therefore be utilised as biomarkers for
treatment selection by stratifying patients according to the
expected response following medical treatment. Furthermore,
genetic biomarkers hold the advantage that they do not change
over time.
Biomarkers able to predict treatment response will help
optimising treatment, reduce adverse side-effects and avoid
treatment with drugs without effect in the individual patients. In
addition, such biomarkers will also help improving the use of health
care resources. The expectations from patients, health care
professionals and health authorities are high. ‘Personalised
medicine represents one of the most innovative new concepts in
health care. It holds real promise for more effective early diagnosis
and more effective and less toxic treatments for patients, for
improved medical service to citizens, and for improving the overall
health of the population’ (http://permed2020.eu/., 2015). ‘Persona-
lised medicine refers to a medical model using characterisation of
individual’s phenotypes and genotypes (for example, molecular
proﬁling, medical imaging, lifestyle data) for tailoring the right
therapeutic strategy for the right person at the right time, and/or to
determine the predisposition to disease and/or to deliver timely
and targeted prevention’ (http://permed2020.eu/., 2015). Until now,
most advances in applied pharmacogenetics have taken place in
the ﬁeld of anticancer therapy.17
Thus, we undertook to review case–control studies on genetic
variants associated with anti-TNF treatment response in RA
patients.
MATERIALS AND METHODS
A systematic review and meta-analysis were carried out according
to the guidelines of ‘Preferred Reporting Items for Systematic
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Reviews and Meta-Analyses’ (PRISMA) statement.18 Three indivi-
dual searches were performed in PubMed combining various
alternative search terms for (1) ‘anti-TNF treatment’, (2) ‘genetic
variation’ and (3) ‘autoimmune disease’, respectively, resulting in
669 abstracts (latest search date: 29th of August 2016). A full list of
search terms is found in Supplementary Table 1. Figure 1 shows
the ﬂow diagram of included studies. All studies suggesting that
they presented original data on associations between polymorph-
isms and anti-TNF treatment response in autoimmune diseases
were retrieved (170 articles) and reviewed by three independent
authors (SiB, JVN, VA). Exclusion criteria were: o100 cases
available for treatment evaluation, missing data on treatment
response, not reporting original data and not reporting data on
anti-TNF response in RA (122 studies). In total, 47 studies reported
association between genetic markers and anti-TNF response in RA.
No further studies were identiﬁed by searching the literature list of
the retrieved articles. Data on study design, number of patients,
response criteria, odds ratios (OR) and 95% conﬁdence intervals
(95% CI) or numbers of good responders, moderate and non-
responders, and genotypes were included.
Statistics
Meta-analysis was performed on studies using EULAR response
criteria.19 All polymorphisms studied in at least two studies (with a
minimum of one signiﬁcant association with response), and where
data on genotypes and treatment response could be retrieved,
were included in a meta-analysis (30 studies). The meta-analysis
was based on the total number of patients in the cohorts.
Figure 1. Flow diagram of included studies.
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Table 1. Description of 43 candidate gene studies (candidate) and 5 GWAS on associations between polymorphisms and response to anti-TNF treatment in RA patients
Disease Ethnicity/country Biological drug(s) DMARDsa (%) MTXa (%) Response criteria bases on Response evaluated after N cases Refs.
Candidate
RA Caucasian, Spain INX/ADM/ETC 100 57.7 ACR/EULAR 1239 Canet et al.29
RA Caucasian, UK INX/ADM/ETC 81.8 — EULARb/ΔDAS28b 3–6 months 1750 Smith et al.23
RA Denmark INX/ADM/ETC 84 73 EULARc 3–6 months 1007 Sode et al.15
RA Denmark INX/ADM/ETC 83 72 EULARc 3–6 months 469 Sode et al.15
RA Caucasian, Poland INX/ADM/ETC — 93 EULARc/ΔDAS28d 12 and 24 weeks 284 Iwaszko et al.24
RA Denmark INX/ADM/ETC 84 — EULAR 2–6 months 538 Sode et al.16
RA Caucasian, Poland INX/ADM/ETC — 92 EULARc/ΔDAS28d 12 and 24 weeks 223 Iwaszko et al.21
RA Spain and Greece INX/ADM/ETC 95 — EULARc/ΔDAS28 3 and 6 months 755 Ferreiro-Iglesias et al.28
RA Multicentere INX/ADM/ETC — 86.2 EULARc 6 months 471 Canet et al.22
RA Portugal INX/ADM/ETC 91.8 82.2 EULARf/ΔDAS28 6 months 383 Canhão et al.58
RA The Netherland ADM — 82.1 EULARg/ΔDAS28 14 weeks 302 Dávila-Fajardo et al.32
RA Spain and Greece INX/ADM/ETC 94.6 — EULAR/ΔDAS28 3, 6 and 12 months 423 Montes et al.33
RA Poland INX/ADM/ETC — 92.5 EULARh/ΔDAS28 6 months 280 Swierkot et al.52
RA Denmark INX/ADM/ETC 84.2 — EULARc/ACR50 3–6 months 538 Sode et al.14
RA Spain and Greece INX/ADM/ETC 88.4 — EULARc/ΔDAS28 3, 6 and 12 months 410 Montes et al.56
RA Spanish INX/ADM/ETC EULAR/ΔDAS28 6 and 12 months 419 Márquez et al.25
RA Spanish INX/ADM/ETC EULAR/ΔDAS28 6 and 12 months 134 Márquez et al.25
RA Japan INX/ADM/ETC 28.7 89.1 EULARc/ΔDAS28 24 weeks 101 Nishimoto et al.31
RA Spain INX/ADM/ETC 78.9 EULARc 6,12,18 and 24 months 199 Dávila-Fajardo et al.31
RA Greece INX/ADM/ETC — — EULARc/ΔDAS28 6 months 183 Zervou et al.55
RA United Kingdom INX/ADM/ETC — — EULARc, g/ΔDAS28 6 months 1278 Mathews et al.44
RA Spain INX/ADM/ETC — — EULARg/ΔDAS28d 12 weeks 315 Acosta-Colman et al.59
RA Italy ADM — — EULAR 12 weeks 377 Ceccarelli et al.30
RA United Kingdom INX/ADM/ETC 73 — EULARg/ΔDAS28d 6 months 1115 Plant et al.47
RA The Netherland INX/ADM — 61.0 EULARi 3 months 182 Coenen et al.38
RA Sweden ADM/ETC — 68.8 EULARi 3 months 269 Coenen et al.38
RA United Kingdom INX/ADM/ETC 68 — ΔDAS28 and EULARc 6 months 1102 Coulthard et al.39
RA United Kingdom INX/ADM/ETC 72 — ΔDAS28 and EULARc 6 months 909 Potter et al.48
RA United Kingdom INX/ADM/ETC 72.7 — ΔDAS28 and EULARf 6 months 1334 Tan et al.53
RA Spain INX/ADM/ETC — — EULARf/ΔDAS28j 3 months 151 Suarez-Gestal et al.51
RA Multi-cohortsk INX/ADM/ETC — 0–100 EULARg/ΔDAS28 3–12 months 1283 Cui et al.40
RA United Kingdom INX/ADM/ETC — — ΔDAS28 6 months 602 Potter et al.36
RA Caucasian INX/ADM/ETC — — EULARi/ΔDAS28 6 months 1050 Hassan et al.41
RA United Kingdom INX/ADM/ETC 73 — ΔDAS28 6 months 624 Bowes et al.26
RA United Kingdom INX/ADM/ETC 68 — ΔDAS28 6 months 411 Bowes et al.26
RA United Kingdom INX/ADM/ETC 69 — EULARg/ΔDAS28 6 months 1050 Maxwell et al.57
RA The Netherland INX/ADM — — ΔDAS28 3 and 6 months 234 Toonen et al.54
RA United Kingdom INX/ADM/ETC 73 — ΔDAS28 6 months 642 Potter et al.49
RA Italy INX/ADM/ETC — — ΔDAS28/ACR20/50/70l 12 months 105 Ongaro et al.45
RA Spain INX — — ΔDAS28d 30 weeks 113 Pinto et al.35
RA France ADM 72 47 ACR50m 12 weeks 388 Miceli-Richard et al.27
JIA Caucasian INX/ADM/ETC ACR Pedi 30 3 months 107 Cimaz et al.37
RA Sweden INX/ ETC — — EULAR/ACR20/50/70l 3 months 282 Kastbom et al.42
JIA Caucasian ETC — — ACR-JRA 30n 3 months 137 Schmeling et al.50
RA France INX — — ARC20o 30 weeks 198 Marotte et al.43
RA Sweden ETC — — ARC20o/ΔDAS28 3 months 123 Padyukov et al.46
GWAS
RA Japanese INX/ADM/ETC — — ΔDAS28 3 and 6 months 444 Honne et al.60
RA Spanish INX/ADM/ETC — — EULAR 12 weeks 361 Julià et al.61
RA Dutch INX/ADM/ETC — — ΔDAS28 3 months 984 Umicevic et.al.64
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Table 1. (Continued )
Disease Ethnicity/country Biological drug(s) DMARDsa (%) MTXa (%) Response criteria bases on Response evaluated after N cases Refs.
RA Danish INX/ADM/ETC — — EULAR/ΔDAS28 14 weeks 196 Krintel et al.62
RA Great Britain INX/ADM/ETC — — ΔDAS28p 6 months 566 Plant et al.63
Abbreviations: ACR, American College of Rheumatology outcome measure % improvement; ADM, adalimumab; DAS28, disease activity score for 28 joints; DMARDs, disease-modifying antirheumatic drugs; ETC,
etanercept; EULAR, European League Against Rheumatism; INX, inﬂixiamb; JIA, juvenile idiopathic arthritis; MTX, methotrexate; RA, rheumatoid arthritis. aTreatment with additional drugs during biological
treatment. bEULAR response was classiﬁed into. Good responders are those withΔDAS28 ⩾ 1, 2 and DAS28 ⩽ 3, 2. Non-responders are all the patients withΔDAS28 o0, 6 and those withΔDAS2840, 6 but ⩽ 1, 2
and DAS2845, 1. All the remaining patients are moderate responders. cEULAR response were deﬁned as good and moderate response. dGood responders are those withΔDAS28 ⩾ 1, 2 and DAS28 ⩽ 3, 2. Non-
responders are all the patients withΔDAS28 o0, 6 and those withΔDAS2840, 6 but ⩽ 1, 2 and DAS2845, 1. All the remaining patients are moderate responders. eSpain, Portugal and Romania. fEULAR deﬁnes
anti-TNF response in three categories: good, moderate and non-response—moderate response were removed and good versus non-response were analysed. gEULAR response were deﬁned as good response.
hEULAR response were deﬁned as remission and low disease activity. iEULAR response were not speciﬁc deﬁned as seen in refs 6 and 7. jAnti-TNF response was evaluated by absolute (ΔDAS28) and relative
(ΔDAS28/DAS28baseline) DAS28 score change. kABCoN (n= 116), AMC (n= 157), BeSt (n= 126), BRAGGSS (n= 81) BRASS (n= 55) EIRA (n= 291), ERA (n= 218), KI (n= 163), JBI (n= 76). lARC20, 50 and 70 responses is
deﬁned if the patients have 20, 50 or 70% improvement in tender and swollen joints, respectively. Patients with ACR20, 50 or 70 response were considered low-, medium and high responders, respectively.
mARC50 is deﬁned as responder if 20% improvement in tender and swollen joints were achieved as well as a 50% improvement in at least three of the ﬁve criteria: Patients assessment, physician assessment,
pain scale, disability/functional questionnaire and acute phase reactant (erythrocyte sedimentation rate or C-reactive protein (CRP)). nARC-JRA 30 is deﬁned as responder if 30% improvement in tender and
swollen joints were achieved as well as a 30% improvement in at least three of the ﬁve criteria: Patients assessment, physician assessment, pain scale, disability/functional questionnaire and acute phase reactant
(erythrocyte sedimentation rate or CRP). oARC20 is deﬁned as responder if 20% improvement in tender and swollen joints were achieved as well as a 20% improvement in at least three of the ﬁve criteria:
Patients assessment, physician assessment, pain scale, disability/functional questionnaire and acute phase reactant (erythrocyte sedimentation rate or CRP). pAnti-TNF response was evaluated by absolute
(ΔDAS28) and relative (ΔDAS28/DAS28baseline) DAS28 score change.
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WDR27, GFRA1, MED15, LINC01387, LOC102723883, CNTN5, NUBPL,
PDZD2, EYA4, TEC and C12orf79 were identiﬁed.
The polymorphisms investigated in candidate gene studies in
relation to the outcome from anti-TNF treatment of patients with
RA and JIA are shown in Supplementary Table 2. Hundreds of
polymorphisms in various pathways have been selected for
evaluation as candidate genes. Many of the assessed polymorph-
isms were found to be associated with response after anti-TNF
treatment in one study. However, only few of these polymorph-
isms have been sought replicated in other candidate gene studies.
Supplementary Table 3 shows the ORs and 95% CI for the
associations between polymorphism and treatment response for
Figure 2. Meta-analyses of 6 polymorphisms in 6 genes, which were associated with treatment response in rheumatoid arthritis (RA).
Table 3. Positive and negative prediction values for selected genotypes in an exploratory analyses based on data from Sode et al.14–16
No. of risk genotypoes Response (n) Non-response (n) Logistic regression predicting non-response Predictive values
Crude OR Adj.OR Adj. 95% CI Pos. Neg.
0 18 3 (Ref. odds= 0.17) — — 0.86 0.14
1 70 30 2.57 3.08 (0.83, 11.49) 0.7 0.3
2 113 55 2.92 3.36 (0.93, 12.13) 0.67 0.33
3 59 52 5.29* 6.03** (1.65, 22.06) 0.53 0.47
4 9 9 6.00* 6.35* (1.32, 30.48) 0.5 0.5
N= 418. Non-response versus full or partial response. Adjusted for: gender, DAS28, HAQ and DMARD status at baseline. Risk genotypes: CHUK rs11591741 (CC),
IKBKB rs11986055 (CC), IFNGR2 rs17882748 (CT/TT), IL6 rs10499563 (CT/TT), NLRP3 rs4612666 (CT/TT). *Po0.05, **Po0.01. Data from Sode et al.14–16
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polymorphisms that were signiﬁcantly associated with response in
more than one cohort. In total, 23 polymorphisms in 21 genes
were identiﬁed. These polymorphisms were selected for meta-
analyses. Figure 2 shows the results for 6 polymorphisms in 6
genes (CHUK, PTPRC, TRAF1/C5, NFKBIB, FCGR2A and IRAK3) that
were associated with treatment response in our meta-analyses.
Supplementary Figure 1 shows the results for 17 polymorphisms
in 16 genes (including FCGR3A, TNF, CD226, MAPKAPKA, RPS6KA5,
MAP2K6, TLR5, TLR1, IFNG, IKBKB and TLR10) that were not
associated with treatment response.
Next, to evaluate the current status of clinical use of the
biomarkers we perform an explorative analysis of one cohort with
available genotyping data.14–16 First, we used logistic regression to
identify genotypes associated with non-response (risk genotypes)
(CHUK rs11591741 (CC), IKBKB rs11986055 (CC), IFNGR2 rs17882748
(CT/TT), IL6 rs10499563 (CT/TT), NLRP3 rs4612666 (CT/TT)). Next,
we calculated the OR and 95% CI based on the number of risk
genotypes (Table 3; Supplementary Table 4). OR for non-response
increased dose-dependently with the number of risk genotypes
carried by the patients. For example, individuals with 4 out of 5
non-response-associated genotypes had an OR of 6.35 (95% CI:
1.32–30.48) and a negative predictive value of 0.5. The reference
group of individuals with none of the ﬁve risk genotypes had the
lowest odds (0.17) for non-response and a positive predictive
value of 0.86 (indicating a somewhat higher chance of effective
treatment than the ﬁrst-best average (60–70%)).
DISCUSSION
We identiﬁed polymorphisms associated with treatment outcome
from anti-TNF treatment in RA patients from 47 studies with
available data (Table 1). Among the 25 polymorphisms that were
identiﬁed, 19 polymorphisms were found in GWS (Table 2). Our
meta-analyses further identiﬁed 6 polymorphisms in 6 genes
(Figure 2). Furthermore, we analysed the potential predictive
power in an exploratory analysis of an available cohort.14–16 We
found increasing OR for carrying increasing numbers of non-
response associated polymorphisms (Table 3; Supplementary
Table 4). However, the positive and negative predictive values
were moderate.
Knowledge on the biological pathways involved in the
treatment response in RA may allow for development of new
treatment strategies. The results suggest that genetic variants in
CTCN5, NUBPL, PD2D2, EYA4 and TEC (from the GWS), and CHUK,
PTPRC, TRAF1/C5, NFKBIB, FCGR2A and IRAK3 (from our meta-
analysis) may be implicated in treatment response to anti-TNF
drugs in RA (Tables 2 and 4, Figure 2 and Supplementary Table 5).
Some of the polymorphisms may indeed be functional or be
linked to functional polymorphisms. Rs3761847 in TRAF1/C5 is
associated with changes in mRNA levels. However, the direction of
the effect differs between tissue types (GTEx, http://www.
gtexportal.org.). Likewise, rs9403 in NFKBIB has been associated
with allele-speciﬁc mRNA levels with the variant alleles having the
highest expression in liver (GTEx, http://www.gtexportal.org.).
FCGR2A rs1801274 is also a missense polymorphism resulting in
a non-conservative amino acid substitution (His to Arg). The
variant receptor has lowered afﬁnity towards CRP.65 The lack of
associations may suggest that the assessed genes are not of major
importance for treatment response provided that the studies had
sufﬁcient power and the investigated polymorphisms are func-
tional themselves or linked to functional polymorphisms. Our
meta-analyses suggested that FCGR3A, TNF, CD226, MAPKAPKA,
RPS6KA5, MAP2K6, TLR5, TLR1, IFNG, IKBKB and TLR10 were not
associated with response after anti-TNF treatment in RA
(Supplementary Figure 1).
Recently, we performed a review and meta-analysis of genes
involved in response to anti-TNF treatment in patients with
inﬂammatory bowel disease (IBD).12 SNPs involved in the TLR
signalling pathway were found to be associated with anti-TNF
treatment response in IBD, thus suggesting a signiﬁcant role for
Table 4. Proposed functions of selected polymorphisms that are identiﬁed in GWS or meta-analysis as associated with treatment response in RA
SNPs Gene MAF Allele Proposed function of genes/proteins and SNPs associated with treatment response in RA
rs3761847 TRAF1 0.46 G Gene/protein function: This protein and TRAF2 form a heterodimeric complex, which is required for
TNF-alpha-mediated activation of MAPK8/JNK and NF-kappaB
SNP function: rs3761847 is associated with changes in mRNA levels. However, the direction of the
effect differs between tissue types (GTEx, http://www.gtexportal.org.). Furthermore, rs3761847GG
homozygotes have higher Gp210 autoantibody as compared with AA homozygotes. In contrast,
rs3761847AA homozygotes have higher antichromatin as compared to GG homozygotes.66 In
addition, rs3761847GG homozygotes increases the risk of death in RA and appears to be
independent of RA activity and severity as well as comorbidities relevant to cardiovascular disease67
rs4612666 NLRP3 0.41 T Gene/protein function: A member of the NALP3 inﬂammasome complex. This complex functions as
an upstream activator of NF-kappaB signalling, and it has a role in the regulation of inﬂammation,
the immune response and apoptosis
SNP function: rs4612666T decreases expression68
rs9403 NFKBIB 0.45 C Gene/protein function: Inhibit NF-kappa-B by complexing with, and trapping it in the cytoplasm
SNP function: rs9403 is associated with changes in mRNA levels. However, the direction of the effect
differs between tissue types (GTEx, http://www.gtexportal.org.)
rs1061622 TNFRSF1B 0.19 G Gene/protein function: The protein encoded by this gene is thought to potentiate TNF-induced
apoptosis by the ubiquitination and degradation of TNF-receptor-associated factor 2, which
mediates anti-apoptotic signals
SNP function: Unknown
rs1801274 FCGR2A 0.44 G Gene/protein function: Member of a family of immunoglobulin Fc receptor genes found on the
surface of many immune response cells that is involved in the process of phagocytosis and clearing
of immune complexes. Autoimmune diseases with elevated circulating autoantibodies drive tissue
damage and the onset of disease. The Fcγ receptors bind IgG subtypes modulating the clearance of
circulating immune complexes.
SNP function: rs1801274 at nucleotide 519 is involved in its ligand binding domain, causing an
arginine (G-allele) to histidine (A-allele) amino acid substitution at position 131. The FcγRIIa-H131
shows higher binding efﬁciency for CRP65 and human IgG2 and IgG3 isoforms, compared to FcγRIIa-
R13169
Abbreviation: CRP, C-reactive protein.
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the host–microbial interaction. Thus, different genes have been
identiﬁed to be involved in RA and IBD treatment response to anti-
TNF therapy. This may suggest that genes involved in the adaptive
immune response may have a larger role in RA than in IBD
treatment response to anti-TNF therapy. However, the role of
host–microbial interactions in RA is not clear. Patients with active
RA were found to have dysbiosis in the gut microbiota that partly
resolved after medical treatment.70 The reason for this observation
and how it may relate to treatment mechanism(s) is not known.
RA is a highly heterogeneous disease in terms of clinical
presentation, prognosis and response to treatment.71 It is likely
that this also applies to the pathogenesis of RA, in fact, studies
have shown pronounced heterogeneity in RA synovial tissue of
inﬂammatory cell types and gene expression.72 Through an
improved discrimination of different RA subsets, SNP associations
may prove to be more clinically useful, as they could at least in
theory be very important for a certain subgroup while irrelevant
for others.
An explorative approach was used when identifying potential
candidate biomarkers in order not to overlook relevant candi-
dates. Response criteria varied between the reviewed studies and
more than one criterion were used in most studies. Our ﬁndings
may furthermore be subject to bias from, for example, publication
bias and selective reporting within studies. Replication of ﬁndings
in other cohorts is of major importance in studies of genetic
epidemiology. Therefore, replication of the ﬁndings in another
cohort was chosen as criterion for association in the present
review. Furthermore, environmental factors such as nutrition,
smoking, lifestyle and other medication may impact genetic
susceptibility and treatment outcome. These factors may not have
been captured in the present studies.
Further evaluation of pharmacogenetics of anti-TNF treatment
response in rheumatoid arthritis including gene–environmental
interactions will require large cohorts of well-characterised
patients and replication of positive ﬁndings in other cohorts. This
work necessitates collaboration between researchers, for example,
via International Consortia. Investigations of genomics combined
with microbiome and mucosa expression proﬁles in each patient
may thus allow us to understand which pathways and cytokines
are deregulated in each case. Such knowledge may be utilised to
select the best treatment for each patient.
However, at present, the pharmacogenomic basis for stratifying
patients according to the expected response to anti-TNF
treatment is not yet available.
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